Novasign is focusing on speeding up bioprocess development to simultaneously reduce timelines and costs of new drugs (antibodies, cells, viral vectors) and biosimilar development. By applying advanced machine learning techniques, i.e., combining artificial intelligence and process knowledge in hybrid-models, process development timelines can significantly be reduced. In-silico process modeling using Novasign’s digital twin application, based on data from a particular design space, enables the identification of ideal process conditions in a highly reduced timeline. Ultimately, the created process models are used for soft sensor applications and advanced process control, enabling industry 4.0 on the shop floor. Novasign is a spin-off from the University of Natural Resources and Life Science Vienna (BOKU) and is currently located in Vienna, Austria.